Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : ARX305 is the only anti-CD70 ADC in active development that targets CD70, a protein that is overexpressed in a broad range of solid and hematologic tumors, giving it the potential to treat a range of liquid and solid tumor cancers, where CD70 is overexpr...
Brand Name : ARX305
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 09, 2022
LOOKING FOR A SUPPLIER?
Reset All
